Most Recent
Mayne can advance damages case against Cosette over $672M merger debacle
US-based drug maker Cosette has lost its bid to stay proceedings alleging it induced the treasurer to reject its $672 million tie-up with Mayne Pharma, with a judge finding Mayne has a right to prosecute its case and would be prejudiced by the delay. 
Judge won’t disqualify himself from hearing Mayne Pharma case
A judge has refused to disqualify himself from case managing Mayne Pharma's latest dispute with US drug maker Cosette over the collapse of their $672 million merger agreement, calling the bid “plainly premature”. 
Greensill can’t access privileged copy of Tokio Marine unit’s database
Collapsed supply chain finance company Greensill Bank can't access a copy of a Tokio Marine unit's database, with a judge finding the copy was created for the primary purpose of HWL Ebsworth providing legal advice.
SkyCity shareholder can’t bring action over $67M AUSTRAC penalty
A SkyCity shareholder has lost his bid to bring a case against former executives and directors at the ASX-listed casino seeking to recoup a $67 million penalty over breaches of money laundering regulations. 
Takeovers Panel says Cosette can’t shutter Mayne’s Adelaide drug plant
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
London City Equities settles with Excelsior over $101M sale
London City Equities has reached a settlement with listed firm Excelsior in a case alleging shareholder oppression over a decision to sell off a subsidiary for $101 million and not distribute the proceeds.
Mayne wins extension of FIRB deadline for Cosette takeover
The Foreign Investment Review Board has extended the deadline for ruling on Cosette's proposed $672 million takeover of Mayne Pharma.
Mayne, Cosette row to be decided on merits after panel resets merger clock
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne wins breathing room in fight to get Cosette merger over the line
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette appeals loss over exit from $672M Mayne Pharma merger
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.